

Application No. 09/724,319
Amendment dated December 15, 2005
Reply to Office Action of August 15, 2005

Amendments to the Specification:

Please replace the paragraph beginning on page 70, line 13 of the specification with the following replacement paragraphs.

Sixty male and female, heterozygous PDAPP transgenic mice, 8.5 to 10.5 months of age were obtained from Charles River Laboratory. The mice were sorted into six groups to be treated with various antibodies directed to A β . Animals were distributed to match the gender, age, parentage and source of the animals within the groups as closely as possible. As shown in Table 10, the antibodies included four murine A β -specific monoclonal antibodies, 2H3 (directed to A β residues 1-12), 10D5 (directed to A β residues 1-16), 266 (directed to A β residues 13-28 and binds to monomeric but not to aggregated AN1792), 21F12 (directed to A β residues 33-42). The cell line designated hybridoma resulting from fusion of SP/20 with A/J mouse spleen: 266.2 producing the antibody 266 has the ATCC accession number PTA-6123, having been deposited on July 20, 2004 at the American Type Culture Collection 10801 University Boulevard, Manassas, VA 20110-2209. A fifth group was treated with an A β -specific polyclonal antibody fraction (raised by immunization with aggregated AN1792). The negative control group received the diluent, PBS, alone without antibody.